Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Project Oncology® - Un pódcast de ReachMD

Categorías:
Guest: Jorge Nieva, MD Can the immune checkpoint inhibitor atezolizumab be safely administered subcutaneously at home for patients with non-small cell lung cancer (NSCLC)? That’s the exact question an ongoing study is seeking to answer, and here to discuss the study’s objective, design, and potential implications for home-based subcutaneous cancer therapies is Dr. Jorge Nivea. He’s an Associate Professor of Clinical Medicine at the University of Southern California’s Keck School of Medicine.